China-based Lynk Pharmaceuticals Co., Ltd has announced that the first patient has been dosed in a Phase III clinical study for its drug candidate LNK01001, which is being developed to treat rheumatoid arthritis (RA). The trial is supported by Lynk’s commercialization partner, Simcere Pharmaceutical Group (HKG: 2096), and is being conducted across multiple centers in China.
LNK01001, a JAK1 inhibitor, has successfully completed three Phase II clinical studies for RA, ankylosing spondylitis (AS), and atopic dermatitis (AD), meeting all primary and secondary endpoints and demonstrating a favorable safety profile. Notably, the drug has not shown any of the major cardiovascular adverse events, thrombosis, severe infections, or malignant tumor formation adverse reactions that have been associated with other JAK inhibitors.- Flcube.com
